Japan approves rheumatoid drug Baricitinib for COVID-19 patients
TOKYO (Reuters) - Japan's health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone.
Eli Lilly & Co's Japan subsidiary had applied to regulators for the new use of the drug in December.
(Reporting by Rocky Swift; Editing by Clarence Fernandez)
(c) Copyright Thomson Reuters 2021. Click For Restrictions -